EUVIMEDEUVIMED entdecken
Crossref

Regenerative Medicine in Vitiligo: From Cellular Replacement to Niche Restoration

Bhavni Oberoi, Vanshika Arora, Somesh Gupta

Dermatological Reviews · 2026-06 · 7 (3)

DOI: 10.1002/der2.70072 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Dermatological Reviews, online erschienen am 27.05.2026. Verfasst von Bhavni Oberoi und 2 weiteren Autor:innen. Die Arbeit nennt 75 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Vitiligo is the most common acquired depigmentary disorder, affecting approximately 0.5%–2% of the global population. Although traditionally considered an autoimmune disease leading to melanocyte destruction, accumulating evidence indicates a multifactorial pathogenesis involving oxidative stress, immune dysregulation, metabolic abnormalities, and impaired regenerative capacity of melanocyte stem cells within the follicular niche. Conventional medical therapies often fail to achieve stable and durable repigmentation in resistant or long‐standing lesions. Regenerative medicine has therefore emerged as a promising therapeutic paradigm aimed at restoring melanocyte populations and re‐establishing a supportive cutaneous microenvironment.

Methods

A narrative review of the literature was conducted to summarize current regenerative approaches for vitiligo. The review focuses on cellular and non‐cellular replacement therapies, microenvironment‐modulating strategies, and hybrid multimodal interventions, with emphasis on the rationale and the clinical outcomes reported in recent studies.

Results

Regenerative therapies can be broadly categorized into cell‐based and cell‐free approaches. Cell‐based modalities include established modalities like cultured melanocyte transplantation, non‐cultured epidermal cell suspension (NCES), follicular melanocyte transplantation, and emerging stem cell‐based therapies. Cell‐free strategies aim to restore the melanocyte niche through both established and experimental modalities like platelet‐rich plasma, mesenchymal stromal stem cell‐derived products, exosomes, and cytokine‐modulating agents, including Janus kinase inhibitors. However, variability in treatment protocols and limited high‐quality randomized controlled trials remain important limitations.

Conclusion

Regenerative medicine represents a promising therapeutic frontier in vitiligo by integrating melanocyte replacement, microenvironment restoration, and immune modulation. Advances in stem cell biology, bioengineering, and precision dermatology may further refine these strategies and enable more durable repigmentation outcomes.

Zitieren

APA

Oberoi, B., Arora, V., & Gupta, S. (2026). Regenerative Medicine in Vitiligo: From Cellular Replacement to Niche Restoration. Dermatological Reviews, 7(3). https://doi.org/10.1002/der2.70072

Vancouver

Oberoi B, Arora V, Gupta S. Regenerative Medicine in Vitiligo: From Cellular Replacement to Niche Restoration. Dermatological Reviews. 2026;7(3). doi:10.1002/der2.70072

BibTeX
@article{Oberoi2026,
  author = {Oberoi, Bhavni and Arora, Vanshika and Gupta, Somesh},
  title = {Regenerative Medicine in Vitiligo: From Cellular Replacement to Niche Restoration},
  journal = {Dermatological Reviews},
  year = {2026},
  volume = {7},
  number = {3},
  doi = {10.1002/der2.70072}
}
Kostenlos starten →